



Express Mail No.: EV473970934US

Sheet 1 of 3

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO. 6750-237-999	APPLICATION NO. 10/690,384
APPLICANT Curtis Wright, IV	
FILING DATE October 20, 2003	ART UNIT 1615

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/MM/	A01	4,573,996	3/4/86	Kwiatek et al.	
/MM/	A02	4,597,961	7/1/86	Etscorn	
/MM/	A03	4,666,441	5/19/87	Audriola et al.	
/MM/	A04	4,781,924	11/1/88	Lee et al.	
/MM/	A05	4,788,064	11/29/88	Patel et al.	
/MM/	A06	4,806,341	2/21/89	Chien	
/MM/	A07	4,837,027	6/6/89	Lee et al.	
/MM/	A08	4,839,174	6/13/89	Baker et al.	
/MM/	A09	4,840,796	6/20/89	Sweet et al.	
/MM/	A10	4,906,169	3/6/90	Chien et al.	
/MM/	A11	4,908,213	3/13/90	Govil et al.	
/MM/	A12	4,943,435	7/24/90	Baker et al.	
/MM/	A13	5,023,084	6/11/91	Chien et al.	
/MM/	A14	5,066,494	11/19/91	Becher	
/MM/	A15	5,120,546	6/9/92	Hansen et al.	
/MM/	A16	5,163,899	11/17/92	Sibalis	
/MM/	A17	5,240,711	8/31/93	Hille et al.	
/MM/	A18	5,560,922	10/1/96	Chien et al.	
/MM/	A19	5,676,373	10/14/97	Sakai et al.	
/MM/	A20	5,676,969	10/14/97	Wick et al.	
/MM/	A21	5,686,112	11/11/97	Liedtke	
/MM/	A22	5,736,154	4/7/98	Fuisz	
/MM/	A23	5,879,701	3/9/99	Audett et al.	
/MM/	A24	5,902,603	5/11/99	Chen et al.	
/MM/	A25	5,919,477	7/6/99	Bevan et al.	
/MM/	A26	5,968,547	10/19/99	Reder	
/MM/	A27	6,007,837	12/28/99	Enscore et al.	
/MM/	A28	6,010,715	1/4/00	Wick et al.	
/MM/	A29	6,018,092	1/25/00	Dunshee	
/MM/	A30	6,143,320	11/7/00	Becher et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
/MM/	B01	EP 0 559 411 A1	09/08/92	EPO.		
/MM/	B02	DE 199 00 645 A1	07/13/00	Germany (with English Abstract)		
/MM/	B03	EP 0 298 297 A1	11/19/91	EPO (with English Abstract)		
	B04					
	B05					
	B06					
	B07					
	B08					
	B09					
	B10					
	B11					
	B12					

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/MM/	C01	Carroll, "Estrogen patch may be safer for heart than pill," Reuters Health, April 2003	
/MM/	C02	Edinboro et al., 1997, "Fatal fentanyl intoxication following excessive transdermal application", J Forensic Sci. Jul;42(4):741-3	
/MM/	C03	Jeal W. & Benfield P., 1997, "Transdermal Fentanyl. A Review of its Pharmacological Properties and Therapeutic Efficacy in Pain Control", Drugs, 53(1):109-138	
/MM/	C04	Jordan WP Jr., 1997, "Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems", Am J Contact Dermat. 8(2):108-13.	
/MM/	C05	Jordan et al., 1998, "Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product", Clin Ther. 20(1):80-7	
/MM/	C06	Kemp et al., 1997, "Postmortem Distribution of Nicotine and Cotinine From a Case Involving the Simultaneous Administration of Multiple Nicotine Transdermal Systems", J. Anal. Toxicol. 21(4):310-313	
/MM/	C07	Korte et al., 1996, "Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients", J Pain Symptom Manage. 11(3):139-46	
/MM/	C08	Mahmood I., 1997, "Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.", Clin Pharmacokinet. 33(2):91-102. Review.	
/MM/	C09	Manitz et al., 1998, "On Mathematical Modeling of Dermal and Transdermal Drug Delivery", J. Pharm. Sci. 87(7):873-879.	
/MM/	C10	Meikle et al., 1996, "Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- a clinical research center study", J Clin Endocrinol Metab. 81(5):1832-40	
/MM/	C11	Meikle et al., 1992, "Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men", J Clin Endocrinol Metab. 74(3):623-8.	
/MM/	C12	Popli S et al., 1983, "Transdermal clonidine for hypertensive patients", Clin Ther. 5(6):624-8.	
/MM/	C13	Riley S et al., 1992, "Comparison of two transdermal nitroglycerin systems: Transderm-Nitro and Nitro-Dur.", Clin Ther. 14(3):438-45	
/MM/	C14	Southam M.A., 1995, "Transdermal Fentanyl Therapy: System Design, Pharmacokinetics and Efficacy", Anti-cancer Drugs 6 Suppl. 3: 29-34	
/MM/	C15	Van Buskirk et al., 1997, "Scale-up Adhesive Transdermal Drug Delivery Systems", Pharm. Res. 14(7):848-852	

NYI-3978716v1

EXAMINER	/Melissa Mercier/ (07/03/2007)	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

NON PATENT LITERATURE DOCUMENTS			
*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/MM/	C16	Wang et al., 2000, "Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study", J Clin Endocrinol Metab. 85(3):964-9.	
/MM/	C17	Woolf et al., 1996, "Self-poisoning among Adults Using Multiple Transdermal Nicotine Patches", J. Toxicol. Clin. Toxicol. 34(6):691-8	

NYI-3978716v1

EXAMINER	/Melissa Mercier/ (07/03/2007)	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		